What is ARA-290?
ARA-290, also called cibinetide, is modeled from the helix B surface of erythropoietin. It was designed to keep EPO-like tissue-protective signaling while avoiding classical erythropoietic stimulation of red blood cell production.[5][3]
The strongest human signal is in small fiber neuropathy, especially sarcoidosis-associated neuropathic symptoms and corneal nerve fiber measures. These studies are small, but they are more clinically developed than most research-market peptides.[1][2][4]
ARA-290, cibinetide, and helix B surface peptide are closely related naming lanes for the same EPO-derived tissue-protective peptide concept. The naming should not be confused with erythropoietin itself, because ARA-290 was engineered around nonerythropoietic repair signaling rather than red-blood-cell stimulation.[3][5]
What ARA-290 is investigated for
ARA-290 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Sarcoidosis-associated small fiber neuropathy
Injectable
Sarcoidosis-associated small fiber neuropathy
Injectable
Corneal nerve regeneration
Injectable
Corneal nerve regeneration
Injectable
Diabetic neuropathy and metabolic control
Injectable
Diabetic neuropathy and metabolic control
Injectable
Tissue-protective signaling
Injectable
Tissue-protective signaling
Injectable
The innate-repair mechanism supports research interest across injury models, but broad tissue-repair treatment claims are not established.[5]
Evidence snapshot
Overall confidence
ARA-290 has meaningful early human neuropathy evidence and a coherent tissue-protective rationale. Sample size, endpoint scope, and missing Phase 3 confirmation keep confidence in the emerging range.[1][4]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Small Phase 2 and randomized studies support sarcoidosis-related small-fiber neuropathy and type 2 diabetes neuropathic-symptom signals. The evidence is still narrow.[1][3][4]
Animal / preclinical
Preclinical tissue-protective studies support the innate-repair rationale behind the human neuropathy work. They should not be generalized into broad tissue-repair claims.[5]
Mechanism support
The engineered EPO helix B design and innate-repair-receptor concept give ARA-290 a clear mechanism. It is designed to avoid erythropoietic signaling.[5][3]
Forms & administration
ARA-290 administration is mainly an injectable clinical-research context. Neuropathy-oriented protocols commonly use a short daily course.[1][3][4]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
What to expect
Weeks 1-4
Injectable neuropathy-oriented use may first show changes in burning pain, numbness, sleep disruption, or day-to-day function.[1]
Weeks 4-8
Pain, function, and sensory symptoms are easier to compare against baseline over a full daily course; objective nerve-fiber changes require clinical testing.[4]
After stopping
Pain relief, function, and sensory comfort may hold or fade after the daily course ends.[2][4]
Safety profile
Injectable ARA-290 safety centers on local tolerability, repeated-course exposure, pregnancy avoidance, oncology context, and whether its nonerythropoietic design holds across chronic use. Small studies provide human tolerability context, but not a mature long-term safety profile.[1][3][4]
Who ARA-290 is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- EPO or erythropoiesis-stimulating therapies
EPO or erythropoiesis-stimulating therapy overlaps with ARA-290's EPO-derived biology; the interaction concern is theoretical because ARA-290 was designed to avoid red-cell stimulation.[3]
Regulatory status
United States
ARA-290/cibinetide has no FDA-approved injectable human use as of 2026-06-21. Research, orphan-style development history, or compounded availability does not create FDA review of safety, effectiveness, quality, or market authorization.[6][7][9]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved As of 2026-06-21, ARA-290/cibinetide was not FDA-approved as an injectable drug. Clinical-trial activity does not create U.S. market authorization.[6][7] | Not Listed As of 2026-06-21, ARA-290/cibinetide was not identified on FDA's reviewed 503A bulk-substance materials for injectable compounding. Compounded preparations are still not FDA-approved drugs.[8][9] |
Injectable
International
EU/Europe, UK, Canada, and Australia should be checked by local product and claim; trial activity and orphan-style development history should not be read as market approval.
Sports & competition
WADA's 2026 Prohibited List does not specifically name ARA-290, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review.[12]
How it works
ARA-290/cibinetide is engineered from erythropoietin biology but is meant to avoid classical red-blood-cell stimulation. Its proposed target is innate repair receptor signaling, a tissue-protective pathway discussed around cell-protection, nerve injury, inflammation, and metabolic stress.[3][5]
That mechanism fits sarcoidosis-associated small fiber neuropathy and corneal nerve-fiber endpoints better than broad pain or longevity claims. The injectable route gives systemic exposure, so the key question is whether receptor-level repair signaling produces durable symptom and nerve-fiber improvements in larger, longer trials in treated patients.[1][4][5]
Research gaps & open questions
What the current literature has not yet settled about ARA-290:
Larger late-stage trials still need to confirm whether ARA-290 meaningfully improves pain, daily function, and nerve-fiber health in people with neuropathy.[1][4]
Studies have not established how long treatment should continue, whether benefits last after stopping, or how safe repeated courses are.[2]
Results in sarcoidosis and diabetic neuropathy cannot answer whether ARA-290 works for other conditions; each condition needs its own trials.[3]
Common questions
How is ARA-290 different from EPO?
What is the best-supported ARA-290 use case?
Myths & misconceptions
Myth
ARA-290 raises red blood cells like EPO.
Reality
It was engineered to retain tissue-protective signaling without classical erythropoietic activity.[3]
Myth
Phase 2 neuropathy data means ARA-290 is an approved neuropathy drug.
History & discovery
ARA-290, later known as cibinetide, grew out of attempts to preserve erythropoietin's tissue-protective signaling while avoiding the red-blood-cell stimulation that makes EPO clinically complicated.[5][1]
A randomized pilot study tested ARA-290 in sarcoidosis-associated small fiber neuropathy, moving the peptide from innate-repair biology into human symptom research.[1]
A type 2 diabetes study extended the tissue-protection idea to metabolic control and neuropathic symptoms, still in a small clinical setting.[3]
Later sarcoidosis work used corneal nerve fiber abundance as an endpoint, creating a measurable but still limited human evidence thread.[4]
12 citations
Show citationsHide citations
- [1]Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.), 2012 Nov 15. human clinical.
- [2]ARA 290 for treatment of small fiber neuropathy in sarcoidosis.Expert opinion on investigational drugs, 2014 Apr. review.
- [3]ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.), 2015 Mar 13. human clinical.
- [4]Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science, 2017 May 1. human clinical.
- [5]Targeting the innate repair receptor to treat neuropathy.Pain reports, 2016 Jul. review.
- [6]Drugs@FDA/openFDA query for ARA-290U.S. Food and Drug Administration / openFDA. database query.
- [7]Drugs@FDA/openFDA query for CibinetideU.S. Food and Drug Administration / openFDA. database query.
- [8]Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic ActU.S. Food and Drug Administration, 2026-05-14. regulatory.
- [9]Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration. official guidance.
- [10]Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisClinicalTrials.gov. clinical trial registry.
- [11]ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)ClinicalTrials.gov. clinical trial registry.
- [12]The 2026 List of Prohibited Substances and MethodsWorld Anti-Doping Agency, 2026. regulatory.


